Evidence map›Paper›PMID 41863513›Full record

ArticleBiotechnology and bioengineering2026

Pseudo Perfusion of Chinese Hamster Ovary (CHO) Cells as a Reliable Platform for Data Generation to Model and Guide Continuous Perfusion Biomanufacturing.

Nikola G Malinov, Shivam Barodiya, Marianthi G Ierapetritou, Eleftherios T Papoutsakis

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Nikola G MalinovDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.ORCID 0000-0002-1684-5484
Shivam BarodiyaDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.ORCID 0000-0002-7891-2021
Marianthi G IerapetritouDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.ORCID 0000-0002-1758-9777
Eleftherios T PapoutsakisDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.ORCID 0000-0002-1077-1277

Funding

Advanced Mammalian Biomanufacturing Innovation Center (AMBIC) NSF EEC-2100502U.S. Food and Drug Administration (FDA) U01FD007695
6 · The paper itself

Abstract

Chinese Hamster Ovary (CHO) cell monoclonal antibody (mAb) production in continuous perfusion has witnessed a renewed interest within the biopharmaceutical industry. Widespread implementation of perfusion biomanufacturing, however, remains hindered by long process development timelines and high costs. Use of predictive scale-down platforms to generate large informative metabolic datasets and guide process development decisions is critical to decreasing a molecule's time to market. While scale-down platforms based on the pseudo perfusion concept have been previously reported, they have not been rigorously validated. They are often limited by oxygen transport or insufficient metabolic characterization, reducing their role to a preliminary screening tool. Here, we report the design and validation of a pseudo perfusion platform based on a phenotype-driven approach to ascertain that the process emulates continuous perfusion characteristics and is not oxygen limited. Beyond metabolic and cell size steady state, we show that our pseudo perfusion design enables cell cycle subpopulation and intracellular antibody expression steady state. We also demonstrate that pseudo perfusion robustly predicts amino acid demands in continuous perfusion bioreactors with exceptional linear correlation across a broad range of cell-specific perfusion rates. When coupling the pseudo perfusion platform developed here with a workflow for metabolic characterization, we significantly augment the dimensionality and reliability of data which can be generated at this scale to gain actionable insights towards perfusion process design, ultimately reducing process development timelines and the associated costs.

Indexed as

Antibodies, MonoclonalBioreactorsCell Culture TechniquesPerfusionAnimalsCHO CellsCricetinaeCricetulusAntibodies, Monoclonalcell cycle analysisimmunofluorescence stainingk‐means clusteringmetabolismperfusionscale‐down

Identifiers

PMID41863513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.